临床药理咨询及其在临床决策中的实施
Mirjam Kauppila1,2,3, Janne T Backman1,2,3, Outi Lapatto-Reiniluoto1,2,3,4
1Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
British journal of clinical pharmacology
|November 19, 2025
概括
临床药理咨询显著影响患者的治疗,其中86%的建议得到了遵守. 该服务为医疗专业人员提供必要的临床和科学支持.
科学领域:
- 临床药理学 临床药理学
- 医疗咨询服务 医疗咨询服务
背景情况:
- 临床药理学家作为跨医学专业的顾问,发挥着至关重要的作用.
- 了解咨询特征对于优化此服务至关重要.
研究的目的:
- 调查临床药理学咨询的特点.
- 为了比较不同医学专业的咨询类型.
- 评估遵守临床药理学建议的情况.
主要方法:
- 对269名患者数据档案进行了回顾性分析.
- 数据收集包括人口统计,咨询专业和咨询特征.
- 评估在商回复中提供的建议的遵守情况.
主要成果:
- 大多数咨询来自赫尔辛基大学医院,主要来自精神病学和通用医学.
- 药物不良反应是精神病学和通用医学中最常见的主题,而药物相互作用在其他专业中是常见的.
- 咨询指令在86%的案例中得到了遵守,显示了高度的遵守.
结论:
- 临床药理咨询显著影响患者治疗策略.
- 这项咨询服务为独立的临床医生提供了宝贵的临床和科学支持.
相关概念视频
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Dosage Regimens: Designs and Approaches
246
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
246
Analysis of Population Pharmacokinetic Data
659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
Dosage Regimens: Partial Pharmacokinetic Parameters
138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138


